Abstract：
ARISE (Aneurysm/AVM/cSDH Roundtable Discussion With Industry and Stroke Experts) organized a one-and-a-half day meeting and workshop and brought together representatives from academia, industry, and government to discuss the most promising approaches to improve outcomes for patients with chronic subdural hematoma (cSDH). The emerging role of middle meningeal artery embolization in clinical practice and the design of current and potential future trials were the primary focuses of discussion. Existing evidence for imaging, indications, agents, and techniques was reviewed, and areas of priority for study and key questions surrounding the development of new and existing treatments for cSDH were identified. Multiple randomized, controlled trials have met their primary efficacy end points, providing high-level evidence that middle meningeal artery embolization is a potent adjunctive therapy to the standard (surgical and nonsurgical) management of neurologically stable cSDH patients in terms of reducing rates of disease recurrence. Pooled data analyses following the formal conclusion and publication of these trials will form a robust foundation upon which guidelines can be strengthened for cSDH treatment modalities and optimal patient selection, as well as delineate future lines of investigation.
摘要：
ARISE（动脉瘤/AVM/cSDH与行业和中风专家的圆桌会议讨论）组织了为期一天半的会议和研讨会，汇集了来自学术界的代表，工业,和政府讨论改善慢性硬膜下血肿（cSDH）患者预后的最有希望的方法。脑膜中动脉栓塞在临床实践中的新兴作用以及当前和潜在的未来试验的设计是讨论的主要焦点。现有的成像证据，适应症,代理商,并审查了技术，确定了研究的重点领域和围绕cSDH新的和现有治疗方法开发的关键问题。多重随机，对照试验已达到其主要疗效终点，提供高水平证据,证明脑膜中动脉栓塞术在降低疾病复发率方面是神经系统稳定的cSDH患者的标准(手术和非手术)治疗的有效辅助治疗.这些试验的正式结论和公布后的汇总数据分析将为加强cSDH治疗模式和最佳患者选择的指南奠定坚实的基础。以及描绘未来的调查路线。
